- Home
- ACB vs DTIL Comparison
ACB vs DTIL Comparison
Compare ACB & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | DTIL |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 194.3M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACB | DTIL |
|---|---|---|
| Price | $3.54 | $7.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.4M | 210.2K |
| Earning Date | 06-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $3.53 |
| 52 Week High | $6.67 | $8.82 |
Technical Indicators
Market Signals| Indicator | ACB | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 56.06 |
| Support Level | $3.22 | $4.56 |
| Resistance Level | $3.91 | $7.84 |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 33.33 | 53.85 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).